Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (11-20 of 379) with videos related to

Pageof 38
Sort By:
Cancer Journal (Sudbury, Mass.)|April 25, 2009
Combined modality treatment of Hodgkin's lymphomaBeate Klimm, Andreas Engert
Cancer Treatment Reviews|April 11, 2006
Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancerJulia Bohlius, Andreas Engert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin LymphomaPeter Borchmann, Andreas Engert
Hemasphere|November 15, 2019
The First Year of HemaSphere and Many More to ComeAndreas Engert, Jan Cools
Nature Clinical Practice. Oncology|May 10, 2006
Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?Volker Diehl, Andreas Engert
Current Opinion in Oncology|July 12, 2017
The genetics of Hodgkin lymphoma: an overview and clinical implicationsSven Borchmann, Andreas Engert
Nature Clinical Practice. Oncology|May 8, 2008
Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignanciesBeate Klimm, Andreas Engert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et alPeter Borchmann, Andreas Engert
Current Opinion in Oncology|July 5, 2021
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
International Journal of Hematology|October 12, 2012
Advances in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Pageof 38

Showing results (11-20 of 379) with videos related to

Sort By:
Pageof 38
Cancer Journal (Sudbury, Mass.)|April 25, 2009
Combined modality treatment of Hodgkin's lymphomaBeate Klimm, Andreas Engert
Cancer Treatment Reviews|April 11, 2006
Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancerJulia Bohlius, Andreas Engert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin LymphomaPeter Borchmann, Andreas Engert
Hemasphere|November 15, 2019
The First Year of HemaSphere and Many More to ComeAndreas Engert, Jan Cools
Nature Clinical Practice. Oncology|May 10, 2006
Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?Volker Diehl, Andreas Engert
Current Opinion in Oncology|July 12, 2017
The genetics of Hodgkin lymphoma: an overview and clinical implicationsSven Borchmann, Andreas Engert
Nature Clinical Practice. Oncology|May 8, 2008
Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignanciesBeate Klimm, Andreas Engert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Reply to H.J.A. Adams et al, E.A. Hawkes et al, and C.F. Hess et alPeter Borchmann, Andreas Engert
Current Opinion in Oncology|July 5, 2021
Current treatment options for nodular lymphocyte-predominant Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
International Journal of Hematology|October 12, 2012
Advances in the treatment of Hodgkin lymphomaDennis A Eichenauer, Andreas Engert
Pageof 38